Intervening in β-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis

Neoplasia

Volumn 13, Issue 2, 2011, Pages 131-144

  Stein, Ulrike ^a   Arlt, Franziska ^a   Smith, Janice ^b   Sack, Ulrike ^b   Herrmann, Pia ^a   Walther, Wolfgang ^a   Lemm, Margit ^b   Fichtner, Iduna ^b   Shoemaker, Robert H ^c   Schlag, Peter M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CALVASCULIN; SULINDAC; T CELL FACTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN HCT116; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG TOLERABILITY; HETEROZYGOTE; HUMAN; HUMAN CELL; LIVER METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SPLEEN TUMOR; TUMOR GROWTH; TUMOR XENOGRAFT; WILD TYPE;

EID: 79951502992     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101172     Document Type: Article

References (58)

1. O'Connell JB, Maggard MA, and Ko CY (2004). Colon cancer survival rateswith the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96, 1420-1425.
2. Christofori G (2006). New signals from the invasive front. Nature 441, 444-450.
3. Stein Uand Schlag PM (2007). Clinical, biological, and molecular aspects of metastasisin colorectal cancer. Recent Results Cancer Res 176, 61-80.
4. Arlt F and Stein U (2009). Colon cancer metastasis: MACC1 and Met as metastaticpacemakers. Int J Biochem Cell Biol 41, 2356-2359.
5. Helfman DM, Kim EJ, Lukanidin E, and Grigorian M (2005). The metastasisassociated protein S100A4: role in tumour progression and metastasis. Br J Cancer 92, 1955-1958.
6. Garrett SC, Varney KM, Weber DJ, and Bresnick AR (2006). S100A4, a mediatorof metastasis. J Biol Chem 281, 677-680.
7. Boye K and Mælandsmo GM (2010). S100A4 and metastasis: a small actor playingmany roles. Am J Pathol 176, 528-535.
8. Takenaga K, Nakanishi H, Wada K, Suzuki M, Matsuzaki O, Matsuura A, and Endo H (1997). Increased expression of S100A4, a metastasis-associated gene, inhuman colorectal adenocarcinomas. Clin Cancer Res 3, 2309-2316.
9. Taylor S, Herrington S, Prime W, Rudland PS, and Barraclough R (2002). S100A4(p9Ka) protein in colon carcinoma and liver metastases: association with carcinomacells and T-lymphocytes. Br J Cancer 86, 409-416.
10. Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, Mikalsen SO, Bjørnland K, Fodstad Ø, and Maelandsmo GM (2003). Nuclear localization of themetastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol 200, 589-595.
11. Cho YG, Kim CJ, Nam SW, Yoon SH, Lee SH, Yoo NJ, Lee JY, and Park WS (2005). Overexpression of S100A4 is closely associated with progression of colorectalcancer. World J Gastroenterol 11, 4852-4856.
12. Gongoll S, Peters G, Mengel M, Piso P, Klempnauer J, Kreipe H, and von Wasielewski R (2002). Prognostic significance of calcium-binding protein S100A4in colorectal cancer. Gastroenterology 123, 1478-1484.
13. Hemandas AK, Salto-Tellez M, Maricar SH, Leong AF, and Leow CK (2006). Metastasis-associated protein S100A4-a potential prognostic marker for colorectalcancer. J Surg Oncol 93, 498-503.
14. Kim JH, Kim CN, Kim SY, Lee JS, Cho D, Kim JW, and Yoon SY (2009). Enhanced S100A4 protein expression is clinicopathologically significant to metastaticpotential and p53 dysfunction in colorectal cancer. Oncol Rep 22, 41-47.
15. Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, et al. (2006). The metastasis-associatedgene S100A4 is a novel target of β-catenin/T-cell factor (TCF) signaling in coloncancer. Gastroenterology 131, 1486-1500.
16. Bienz M and Clevers H (2000). Linking colorectal cancer to Wnt signalling. Cell 103, 311-320.
17. Markowitz SD and Bertagnolli MM (2009). Molecular origins of cancer: molecularbasis of colorectal cancer. N Engl J Med 361, 2449-2460.
18. Gavert N and Ben-Ze'ev A (2007). β-Catenin signaling in biological control and cancer. J Cell Biochem 102, 820-828.
19. Klaus A and Birchmeier W (2008). Wnt signalling and its impact on developmentand cancer. Nat Rev Cancer 8, 387-398.
20. Gardner SH, Hawcroft G, and Hull MA (2004). Effect of nonsteroidal antiinflammatorydrugs on β-catenin protein levels and catenin-related transcriptionin human colorectal cancer cells. Br J Cancer 91, 153-163.
21. Koornstra JJ, Rijcken FE, Oldenhuis CN, Zwart N, van der Sluis T, Hollema H, deVries EG, Keller JJ, Offerhaus JA, Giardiello FM, et al. (2005). Sulindac inhibitsβ-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectalcancer and familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 14, 1608-1612.
22. Han A, Song Z, Tong C, Hu D, Bi X, Augenlicht LH, and Yang W (2008). Sulindac suppresses β-catenin expression in human cancer cells. Eur J Pharmacol 583, 26-31.
23. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, and Ahnen DJ (2003). Sulindac metabolites induce caspase- and proteasome-dependent degradationof β-catenin protein in human colon cancer cells. Mol Cancer Ther 2, 885-892.
24. Orner GA, Dashwood WM, Blum CA, Díaz GD, Li Q, and Dashwood RH (2003). Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of β-catenin signalling by a combination of tea plus sulindac. Carcinogenesis 24, 263-267.
25. Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van derNeut R, and Pals ST (2004). Sulindac targets nuclear β-catenin accumulationand Wnt signalling in adenomas of patients with familial adenomatous polyposisand in human colorectal cancer cell lines. Br J Cancer 90, 224-229.
26. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, and Kinzler KW (1998). Identification of c-MYC as a target of the APC pathway. Science 281, 1509-1512.
27. Tetsu O and McCormick F (1999). β-Catenin regulates expression of cyclin D1in colon carcinoma cells. Nature 398, 422-426.
28. Boon EM, van der Neut R, van de Wetering M, Clevers H, and Pals ST (2002). Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectalcancer. Cancer Res 62, 5126-5128.
29. Kim JS, Crooks H, Dracheva T, Nishanian TG, Singh B, Jen J, and Waldman T (2002). Oncogenic β-catenin is required for bone morphogenetic protein 4expression in human cancer cells. Cancer Res 62, 2744-2748.
30. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, and Bodmer WF (1997). β-Catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 94, 10330-10334.
31. Engelkamp D, Schafer BW, Erne P, and Heizmann CW (1992). S100 α, CAPL, and CACY: molecular cloning and expression analysis of three calcium bindingproteins from human heart. Biochem 31, 10258-10264.
32. Hernan R, Fasheh R, Calabrese C, Frank AJ, Maclean KH, Allard D, Barraclough R, and Gilbertson RJ (2003). ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 63, 140-148.
33. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W, and Schlag PM (2009). MACC1, a newly identified key regulator of HGF/MET signalingis a powerful predictor of colon cancer metastasis. Nature Med 15, 59-67.
34. Clevers H (2006). Colon cancer-understanding how NSAIDs work. N Engl JMed 354, 761-763.
35. Szabo E (2006). Selecting targets for chemoprevention: where do we go from here? Nat Rev Cancer 6, 867-874.
36. Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al. (2008). Difluoromethylornithineplus sulindac for the prevention of sporadic colorectal adenomas: a randomizedplacebo-controlled, double-blind trial. Cancer Prev Res 1, 32-38.
37. Sporn MB and Hong WK (2008). Concomitant DFMO and sulindac chemopreventionof colorectal adenomas: a major clinical advance. Nat Clin Pract Oncol 5, 628-629.
38. Tuma R (2008). Drugs to prevent colon cancer show promise, but hurdles remainfor chemoprevention. J Natl Cancer Inst 100, 764-766.
39. Kundu JK (2006). β-Catenin-mediated signaling: a novel molecular target forchemoprevention with anti-inflammatory substances. Biochim Biophys Acta 1765, 14-24.
40. Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, and Richel DJ (2008). Cyclooxygenase-2 inhibition inhibitsc-Met kinase activity and Wnt activity in colon cancer. Cancer Res 68, 1213-1220.
41. Ambartsumian NS, Grigorian MS, Larsen IF, Karlstrøm O, Sidenius N, Rygaard J, Georgiev G, and Lukanidin E (1996). Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene 13, 1621-1630.
42. Davies MP, Rudland PS, Robertson L, Parry EW, Jolicoeur P, and Barraclough R (1996). Expression of the calcium-binding protein S100A4 (p9Ka) in MMTVneutransgenic mice induces metastasis of mammary tumours. Oncogene 13, 1631-1637.
43. Grum-Schwensen B, Klingelhofer J, Berg CH, El-Naaman C, Grigorian M, Lukanidin E, and Ambartsumian N (2005). Suppression of tumor developmentand metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res 65, 3772-3780.
44. Takenaga K, Nakamura Y, and Sakiyama S (1997). Expression of antisense RNAto S100A4 gene encoding an S100-related calcium-binding protein suppressesmetastatic potential of high-metastatic Lewis lung carcinoma cells. Oncogene 14, 331-337.
45. Bjornland K, Winberg JO, Odegaard OT, Hovig E, Loennechen T, Aasen AO, Fodstad O, and Maelandsmo GM (1999). S100A4 involvement in metastasis: deregulationof matrix metalloproteinases and tissue inhibitors of matrix metalloproteinasesin osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res 59, 4702-4708.
46. Shi Y, Zou M, Collison K, Baitei EY, Al-Makhalafi Z, Farid NR, and Al-Mohanna FA (2006). Ribonucleic acid interference targeting S100A4 (Mts1) suppressestumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab 91, 2373-2379.
47. Bottone FG Jr, Moon Y, Kim JS, Alston-Mills B, Ishibashi M, and Eling TE (2005). The anti-invasive activity of cyclooxygenase inhibitors is regulated bythe transcription factor ATF3 (activating transcription factor 3). Mol Cancer Ther 4, 693-703.
48. Tarabykina S, Griffiths TR, Tulchinsky E, Mellon JK, Bronstein IB, and Kriajevska M (2007). Metastasis-associated protein S100A4: spotlight on its role in cell migration. Curr Cancer Drug Targets 7, 217-228.
49. Kunte DP, Wali RK, Koetsier JL, and Roy HK (2008). Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase. Mol Cancer Ther 7, 1797-1806.
50. Williams CS, Goldman AP, Sheng H, Morrow JD, and DuBois RN (1999). Sulindacsulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia 1, 170-176.
51. Sherbet GV (2009). Metastasis promoter S100A4 is a potentially valuable moleculartarget for cancer therapy. Cancer Lett 280, 15-30.
52. Sack U and Stein U (2009). Wnt up your mind-intervention strategies for S100A4-induced metastasis in colon cancer. Gen Physiol Biophys 28, F55-F64.
53. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, Bruseo C, Wood AW, and Shivdasani RA (2004). Small-molecule antagonists of the oncogenic TCF/β-catenin protein complex. Cancer Cell 5, 91-102.
54. Dihlmann S and von Knebel Doeberitz M (2005). Wnt/β-catenin-pathway as amolecular target for future anti-cancer therapeutics. Int J Cancer 113, 515-524.
55. Barker N and Clevers H (2006). Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 5, 997-1014.
56. Rajamanickam S, Kaur M, Velmurugan B, Singh RP, and Agarwal R (2009). Silibininsuppresses spontaneous tumorigenesis in APC min/+ mouse model by modulatingβ-catenin pathway. Pharm Res 26, 2558-2567.
57. Chen M, Sinha M, Luxon BA, Bresnick AR, and O'Connor KL (2009). Integrinα6β4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin. J Biol Chem 284, 1484-1494.
58. Zhang R, Fu H, Chen D, Hua J, Hu Y, Sun K, and Sun X (2010). Subcellulardistribution of S100A4 and its transcriptional regulation under hypoxic conditionsin gastric cancer cell line BGC823. Cancer Sci 101, 1141-1146.